Search Results for:
-
Phytopharm Falls on Cogane Failure, Seeks Strategic Review
It looks pretty unambiguous, and it also looks as if the study was well conducted," Sharpington told BioWorld InternationalBio Perspectives | Wednesday, February 20, 2013 -
Diamyd Staves Off Liquidation, Returns Cash to Shareholders
We were able to avoid liquidation of the company," Chairman Anders Essen-Möller, who holds 33.92 percent of the votes in the Stockholm, Sweden-based company, told BioWorld International...J&J, of New Brunswick, N.J., originally had stumped up $45 million up front in a deal valued at up to $625 million in total. (See BioWorld Today, May 10, 2011, and BioWorld International, June 8, 2011.) Its market capitalization has often dropped below its cash balance since then, which has led to volatility inBy Cormac Sheridan | BioWorld International | Wednesday, February 20, 2013 -
FDA Accepts Zealand's GLP-1 Drug Lixisenatide for Review
It's a reasonable expectation that we'll hear back from the FDA within a year," David Solomon, CEO of Copenhagen, Denmark-based Zealand, told BioWorld InternationalBy Cormac Sheridan | BioWorld International | Wednesday, February 20, 2013 -
Phytopharm Falls on Cogane Failure, Seeks Strategic Review
It looks pretty unambiguous, and it also looks as if the study was well conducted," Sharpington told BioWorld InternationalBy Nuala Moran and Cormac Sheridan | BioWorld International | Wednesday, February 20, 2013 -
Swiss Start-up Piqur Develops Dual PI3K-mTOR Inhibitors
What Piqur has today are molecules, which have significantly improved physico-chemical properties, leading to the improved pharmacological properties," Cmiljanovic told BioWorld InternationalBy Cormac Sheridan | BioWorld International | Wednesday, February 13, 2013 -
e-Therapeutics Raises $63M to Fund Solid Tumor Drug
it can't be cheap," he told BioWorld InternationalBy Nuala Moran | BioWorld International | Wednesday, February 13, 2013 -
Medgenics Lays More Runway for Biopump with $30M Raise
The aim was to raise between $20 million and $30 million, so this was at the higher end, and in the event "some folks didn't get in," Pearlman told BioWorld InternationalBy Nuala Moran | BioWorld International | Wednesday, February 13, 2013 -
Scientists Direct Focus on Targeting Short-Sight Genes
Caroline Klaver, professor of ophthalmology and epidemiology at Erasmus Medical Centre in Rotterdam, the Netherlands, and joint director of the multinational study, told BioWorld International: "The consortium is going to continue to work closely together to define the common pathways in which these newly discovered genes operate and how they communicate with each otherBy Sharon Kingman | BioWorld International | Wednesday, February 13, 2013 -
Venture Capital And Other Investments In Private Biotechnology Companies: January 2013
Redwood City, Calif. $25 Versartis raised $25M in a Series C round with Aisling Capital, Index Ventures, New Leaf Partners and Advent Venture Partners 1/16/13 Notes: Currency conversions are based on exchange rates at the time of the deal. ** Denotes the date the item ran in BioWorld InternationalBioWorld Insight | Monday, February 11, 2013 -
'Safari,' So Good: Africa Tracks to Become Pharma Hot Spot
The fact is, Africa has stabilized," Rosen told BioWorld InternationalBio Perspectives | Wednesday, February 6, 2013 -
New Era Beckons for Zealand as Lyxumia Gains Approval
Zealand CEO David Solomon told BioWorld International...Additional information will be provided at the time of individual country launches," Phil McNamara, spokesman for Sanofi's global diabetes division, told BioWorld InternationalBio Perspectives | Wednesday, February 6, 2013 -
BIA Widening Public Start-up Biotech Investment via CIFs
In addition, since the BIA first put forward the plan in September 2012, it has had a number of positive discussions with other organizations which are interested in the scheme. (See BioWorld International, Sept. 5, 2012.) Figures for the French innovation funds show that for every €1 in tax relief given by the government, €5 of additional private investment is raisedBy Nuala Moran | BioWorld International | Wednesday, February 6, 2013 -
Let 'EdRIP': VC Fund Seeks $677M for Life Science Firms
Litzka told BioWorld International that €250 million remains as the ambition, but "economic realities" may mean the final close is lowerBy Nuala Moran | BioWorld International | Wednesday, February 6, 2013 -
New Era Beckons for Zealand as Lyxumia Gains Approval
Zealand CEO David Solomon told BioWorld International...Additional information will be provided at the time of individual country launches," Phil McNamara, spokesman for Sanofi's global diabetes division, told BioWorld InternationalBy Cormac Sheridan | BioWorld International | Wednesday, February 6, 2013 -
AC Immune Drops ACI-91 on Phase II Alzheimer's Failure
They had activity showing they could protect neurons against the toxic effects of Abeta," AC Immune CEO Andrea Pfeifer told BioWorld InternationalBy Cormac Sheridan | BioWorld International | Wednesday, February 6, 2013 -
Control of Cancer, Not Killing, Is Key to Treatment: Study
Martin Röcken, director of the department of dermatology of the University Medical Center Tübingen, told BioWorld International: "We are currently applying for a grant to fund a study of this therapy in patients with metastatic malignant melanoma, in which we would take the patient's T cells, prime them with a cancer peptide and then put them back in to the patient's bodyBy Sharon Kingman | BioWorld International | Wednesday, February 6, 2013 -
Gamida Cell's StemEx Improves Overall Survival in Phase II/III
Partnering has significant advantages, but you have to find the right partner," Margolin told BioWorld International, noting that the company will entertain those discussions after meeting with the FDABy Marie Powers | BioWorld International | Wednesday, February 6, 2013 -
'Safari,' So Good: Africa Tracks to Become Pharma Hot Spot
The fact is, Africa has stabilized," Rosen told BioWorld InternationalBy Randy Osborne | BioWorld International | Wednesday, February 6, 2013 -
Active Biotech's Immunotherapy Anyara Is Down but Not Out
We're encouraged that we got a robust signal," CEO Thomas Leanderson told BioWorld InternationalBio Perspectives | Wednesday, January 30, 2013 -
Active Biotech's Immunotherapy Anyara Is Down but Not Out
We're encouraged that we got a robust signal," CEO Thomas Leanderson told BioWorld InternationalBy Cormac Sheridan | BioWorld International | Wednesday, January 30, 2013
Category
Current Filters
- xBioWorld International
Related Keywords
Categories
- x BioWorld International (5388)
- x BioWorld Insight (593)
- x BioWorld Today (332)
- x Bio Perspectives (192)
- x State of the Industry Report (47)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.